Cornelia F Allaart

12.7k citations

189 papers · 7.3k indexed · 2 hit papers · h-index 46

Co-authors: T. Huizinga Ben A. C. Dijkmans P. J. S. M. Kerstens Jeska K de Vries‐Bouwstra H. K. Ronday Willem F. Lems Y P M Goekoop-Ruiterman J.H.L.M. van Groenendael
Topics: Rheumatoid Arthritis Research and Therapies (156 papers)Systemic Lupus Erythematosus Research (67 papers)Autoimmune and Inflammatory Disorders Research (46 papers)
Cited by: Rheumatology Hematology Genetics
Journals: The LancetSHILAP Revista de lepidopterologíaAnnals of Internal Medicine
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Cornelia F Allaart

183 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial

2005 1.1k citations Y P M Goekoop-Ruiterman, Jeska K de Vries‐Bouwstra et al. Arthritis & Rheumatism profile →
Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial

2022 96 citations Marc R. Kok, Pascal H P de Jong et al. profile →

Peers

Countries citing papers authored by Cornelia F Allaart

Since Specialization

Citations

This map shows the geographic impact of Cornelia F Allaart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cornelia F Allaart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cornelia F Allaart more than expected).

Fields of papers citing papers by Cornelia F Allaart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cornelia F Allaart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cornelia F Allaart. The network helps show where Cornelia F Allaart may publish in the future.

Co-authorship network of co-authors of Cornelia F Allaart

This figure shows the co-authorship network connecting the top 25 collaborators of Cornelia F Allaart. A scholar is included among the top collaborators of Cornelia F Allaart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cornelia F Allaart. Cornelia F Allaart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rheumatoid arthritis-associated interstitial lung disease in countries across the world 2025 ·Seminars in Arthritis and Rheumatism ·(unknown),(unknown),(unknown),Arvind Chopra,David Vega‐Morales,R Du Toit,(unknown),(unknown),Carlos Enrique Toro Gutiérrez,Rachel Knevel,Annette H M van der Helm–van Mil,T. Huizinga,Cornelia F Allaart,Sytske Anne Bergstra	0
2	Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies 2024 ·Lara D. Veeken ·(unknown),(unknown),(unknown),Paul Baudoin,Gerda M. Steup‐Beekman,T. Huizinga,Sytske Anne Bergstra,Cornelia F Allaart	4
3	Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? 2023 ·Annals of the Rheumatic Diseases ·(unknown),Patrick Verschueren,Maarten Boers,Paul Emery,Pascal H P de Jong,Robert Landewé,Willem F. Lems,Josef S Smolen,T. Huizinga,Cornelia F Allaart,Sytske Anne Bergstra	3
4	Patterns of clinical joint inflammation in juvenile idiopathic arthritis 2023 ·RMD Open ·(unknown),(unknown),J. Merlijn van den Berg,Dieneke Schonenberg‐Meinema,Lisette W. A. van Suijlekom‐Smit,Marion A. J. van Rossum,(unknown),R. ten Cate,D. M. C. Brinkman,T. Huizinga,Cornelia F Allaart,Sytske Anne Bergstra	5
5	Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial 2023 ·Annals of the Rheumatic Diseases ·(unknown),Maarten Boers,Linda Hartman,Daniela Opriș-Belinski,Reinhard Bos,Marc R. Kok,José António Pereira da Silva,E. N. Griep,Ruth Klaasen,Cornelia F Allaart,Paul Baudoin,Hennie G. Raterman,Zoltán Szekanecz,Frank Buttgereit,P. Masaryk,Willem F. Lems,Yvo M. Smulders,Maurizio Cutolo,Marieke M. ter Wee	9
6	Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis 2023 ·Seminars in Arthritis and Rheumatism ·(unknown),Sytske Anne Bergstra,(unknown),T. Huizinga,Rachel Knevel,Cornelia F Allaart	1
7	Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort 2023 ·Annals of the Rheumatic Diseases ·(unknown),(unknown),Saskia le Cessie,Y P M Goekoop-Ruiterman,Melek Güler-Yüksel,Willem F. Lems,T. Huizinga,Sytske Anne Bergstra,Cornelia F Allaart	6
8	Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment 2023 ·RMD Open ·(unknown),Sytske Anne Bergstra,Yvonne P M Goekoop-Ruiterman,Melek Güler-Yüksel,Willem F. Lems,X. Matthijssen,M. van Oosterhout,T. Huizinga,Cornelia F Allaart	4
9	Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort 2023 ·RMD Open ·(unknown),Jacopo Ciaffi,(unknown),(unknown),(unknown),Liesbeth J J Beaart-van de Voorde,(unknown),(unknown),Maarten K. Ninaber,(unknown),(unknown),Maarten E. Tushuizen,Nina Ajmone Marsan,Philippine Kiès,Anne A. Schouffoer,T. Huizinga,Cornelia F Allaart,Jeska de Vries‐Bouwstra	4
10	The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial 2022 ·Lara D. Veeken ·(unknown),Eva M. Hoekstra,Femke Bonte‐Mineur,César Magro‐Checa,Anne A. Schouffoer,Cornelia F Allaart,T. Huizinga,Sytske Anne Bergstra,Jeska K de Vries‐Bouwstra	2
11	IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples 2022 ·Arthritis & Rheumatology ·Theresa Kissel,Lise Hafkenscheid,(unknown),Mami Tamai,Shin‐ya Kawashiri,Atsushi Kawakami,Hani El‐Gabalawy,Dirkjan van Schaardenburg,Solbritt Rantapää‐Dahlqvist,Manfred Wuhrer,Annette H M van der Helm–van Mil,Cornelia F Allaart,Diane van der Woude,Hans Ulrich Scherer,René E. M. Toes,T. Huizinga	35
12	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial 2022 ·Annals of the Rheumatic Diseases ·Maarten Boers,Linda Hartman,Daniela Opriș-Belinski,Reinhard Bos,Marc R. Kok,José António Pereira da Silva,Eduard N. Griep,Ruth Klaasen,Cornelia F Allaart,Paul Baudoin,Hennie G. Raterman,Zoltán Szekanecz,Frank Buttgereit,P. Masaryk,(unknown),Sabrina Paolino,(unknown),Willem F. Lems,Maurizio Cutolo,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	83
13	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis 2022 ·Annals of the Rheumatic Diseases ·(unknown),Andriko Palmowski,(unknown),Frank Buttgereit,Patrick Verschueren,Josef S Smolen,Robert Landewé,(unknown),Andreas Kerschbaumer,René Westhovens,T. Huizinga,Cornelia F Allaart,Sytske Anne Bergstra	15
14	Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count 2021 ·Lara D. Veeken ·Linda Hartman,Maurizio Cutolo,Reinhard Bos,Daniela Opriș-Belinski,Marc R. Kok,(unknown),Ruth Klaasen,Cornelia F Allaart,George A. W. Bruyn,Hennie G. Raterman,Marieke Voshaar,Nuno Gomes,Rui M. A. Pinto,(unknown),Willem F. Lems,Maarten Boers	7
15	New risk model is able to identify patients with a low risk of progression in systemic sclerosis 2021 ·RMD Open ·(unknown),(unknown),(unknown),Jacopo Ciaffi,Nina Ajmone Marsan,Maarten K. Ninaber,Cornelia F Allaart,(unknown),Robbert J Goekoop,T. Huizinga,Rachel Knevel,Jeska de Vries‐Bouwstra	4
16	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy 2017 ·Lara D. Veeken ·Sytske Anne Bergstra,Robert Landewé,T. Huizinga,Cornelia F Allaart	4
17	Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment 2016 ·Annals of Internal Medicine ·I.M. Markusse,(unknown),Linda Dirven,Yvonne P M Goekoop-Ruiterman,J.H.L.M. van Groenendael,(unknown),(unknown),Saskia le Cessie,Willem F. Lems,Peter A. H. M. van der Lubbe,P. J. S. M. Kerstens,André J. Peeters,H. K. Ronday,P. B. J. de Sonnaville,I. Speyer,Theo Stijnen,S. ten Wolde,T. Huizinga,Cornelia F Allaart	2
18	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study 2013 ·Lara D. Veeken ·Shintaro Hirata,Linda Dirven,Yijing Shen,Michael Centola,G. Cavet,Willem F. Lems,Yoshiya Tanaka,T. Huizinga,Cornelia F Allaart	70
19	Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise? 2012 ·Data Archiving and Networked Services (DANS) ·(unknown),(unknown),Cornelia F Allaart,D. M. C. Brinkman,(unknown),J. Merlijn van den Berg,(unknown),R. ten Cate,Martine C. de Vries	1
20	Remission Induction Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid and Undifferentiated Arthritis. 2011 ·Arthritis & Rheumatism ·(unknown),L. Heimans,K. Visser,H. K. Ronday,(unknown),Patrick Seys,C. Bijkerk,M L Westedt,(unknown),(unknown),T. Huizinga,Cornelia F Allaart	4

About Cornelia F Allaart

Cornelia F Allaart is a scholar working on Rheumatology, Hematology and Genetics, having authored 189 papers that have together received 7.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (156 papers), Systemic Lupus Erythematosus Research (67 papers) and Autoimmune and Inflammatory Disorders Research (46 papers). The work is most often cited by research in Rheumatology (6.1k citations), Hematology (2.1k citations) and Genetics (1.3k citations). Cornelia F Allaart has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include T. Huizinga, Ben A. C. Dijkmans, P. J. S. M. Kerstens, Jeska K de Vries‐Bouwstra, H. K. Ronday, Willem F. Lems, Y P M Goekoop-Ruiterman, J.H.L.M. van Groenendael, F. C. Breedveld and K. H. Han. Their work appears in journals such as The Lancet, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact